Predictive Biomarkers Can Be Supported By Two Well-Conducted Retrospective Studies - FDA Advisors
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee considers biomarker validation in context of KRAS biomarker for the cancer agents Vectibix and Erbitux
You may also be interested in...
FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26
FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26
FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers
The Oncologic Drugs Advisory Committee will determine the legitimacy of retrospective trials used to determine predictive biomarkers during review of K-ras data for Erbitux and Vectibix.